Leerink Partners analyst Andrew Berens maintained a Buy rating on Turning Point Therapeutics (NASDAQ:TPTX) Inc on Thursday, setting a price target of $156, which is approximately 140.15% above the present share price of $64.96.
Berens expects Turning Point Therapeutics Inc to post earnings per share (EPS) of -$1.02 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Turning Point Therapeutics, with an average price target of $164.75.
The analysts price targets range from a high of $178 to a low of $150.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$47.94 million. The company's market cap is $3.19 billion.
According to TipRanks.com, Leerink Partners analyst Andrew Berens is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.0% and a 57.86% success rate.
Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. It focuses on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.